In early 2000, a protein–polysaccharide conjugate vaccine targeting seven pneumococcal serotypes was licensed in the United States for use in young children.We examined population-based data ...

The pneumococcal vaccine prepared by Wyeth Lederle Vaccines (Pearl River, N.Y.) consisted of 2 μg each of capsular polysaccharides of pneumococcal serotypes 4, 9V, 14, 19F, and 23F, 4 μg of ...

It protects against 23 serotypes of pneumococcal bacteria. It has polysaccharides unique to the serotypes, but they are not attached to a protein. Two groups may receive PPSV23.

Scientists have identified over 100 pneumococcal serotypes; however, of these, only two, namely, a 23-valent pneumococcal polysaccharide vaccine (PPV23) and pneumococcal conjugate vaccines ...

In Massachusetts, the incidence of invasive pneumococcal infection fell after introduction of the heptavalent conjugated pneumococcal vaccine, then stabilized because of infections from nonvaccine ...

All seven of the new serotypes included in 20vPnC are global causes of invasive pneumococcal disease, 1,2,3,4,5 and six of the seven serotypes (8, 10A, 11A, 15BC, 22F and 33F) 6,7,8,9 are ...

New serotypes of pneumococcus have begun to colonize the nasopharynx of children since the introduction of the PCV13 vaccine in 2010, according to recent research data.“Here we provided analysis ...

Pn-MAPS24V is a novel 24-valent pneumococcal vaccine that contains the 13 serotypes in PCV13, an additional 10 included in PPSV23, and 20B. In a phase 1/2 study compared with PCV13, it was safe ...

The injectable drug, Capvaxive (Pneumococcal 21-valent Conjugate Vaccine), protects against 22 serotypes that cause invasive pneumococcal disease in adults, the company said in a news release.

The V114 vaccine candidate consists of pneumococcal polysaccharides from 15 serotypes, including serotypes 22F and 33F, which are associated with invasive pneumococcal disease. Menu SECTIONS Home ...

Merck's (MRK) Vaxneuvance includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.